tradingkey.logo

Ekso Bionics Holdings Inc

EKSO
查看詳細走勢圖
4.860USD
+0.040+0.83%
收盤 12/19, 16:00美東報價延遲15分鐘
12.75M總市值
虧損本益比TTM

Ekso Bionics Holdings Inc

4.860
+0.040+0.83%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.83%

5天

+4.07%

1月

+25.58%

6月

+68.75%

今年開始到現在

-46.89%

1年

-44.15%

查看詳細走勢圖

TradingKey Ekso Bionics Holdings Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Ekso Bionics Holdings Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名77/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價7.75。中期看,股價處於平穩狀態。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Ekso Bionics Holdings Inc評分

相關信息

行業排名
77 / 208
全市場排名
188 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
買入
評級
7.750
目標均價
+75.34%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Ekso Bionics Holdings Inc亮點

亮點風險
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
業績高增長
公司營業收入穩步增長,連續3年增長38.82%
業績增長期
公司處於發展階段,最新年度總收入17.93M美元
估值高估
公司最新PE估值-0.90,處於3年歷史高位
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉35.45K股

Ekso Bionics Holdings Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Ekso Bionics Holdings Inc簡介

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
公司代碼EKSO
公司Ekso Bionics Holdings Inc
CEODavis (Scott G)
網址https://eksobionics.com/

常見問題

Ekso Bionics Holdings Inc(EKSO)的當前股價是多少?

Ekso Bionics Holdings Inc(EKSO)的當前股價是 4.860。

Ekso Bionics Holdings Inc 的股票代碼是什麼?

Ekso Bionics Holdings Inc的股票代碼是EKSO。

Ekso Bionics Holdings Inc股票的52週最高點是多少?

Ekso Bionics Holdings Inc股票的52週最高點是14.975。

Ekso Bionics Holdings Inc股票的52週最低點是多少?

Ekso Bionics Holdings Inc股票的52週最低點是2.730。

Ekso Bionics Holdings Inc的市值是多少?

Ekso Bionics Holdings Inc的市值是12.75M。

Ekso Bionics Holdings Inc的淨利潤是多少?

Ekso Bionics Holdings Inc的淨利潤為-11.33M。

現在Ekso Bionics Holdings Inc(EKSO)的股票是買入、持有還是賣出?

根據分析師評級,Ekso Bionics Holdings Inc(EKSO)的總體評級為買入,目標價格為7.750。

Ekso Bionics Holdings Inc(EKSO)股票的每股收益(EPS TTM)是多少

Ekso Bionics Holdings Inc(EKSO)股票的每股收益(EPS TTM)是-5.410。
KeyAI